Literature DB >> 6085416

[Treatment of cervical and vulvar condylomata by co2 laser also with a immunostimulant].

G Sadoul, T Beuret.   

Abstract

Condylomata are of viral origin and are found in increasing frequency. The CO2 laser has contributed significantly to the treatment of this condition with a failure rate approximating 35 p. cent of cases. Two groups of patients with cervical or vulvovaginal condylomata were treated by CO2 laser or by CO2 laser and Isoprinosine. After the initial treatment, there were 31,6 p. cent failures in the group treated only by CO2 laser in patients with cervical condylomata, and 66,3 p. cent failures in those with vulvovaginal condylomata. Following 3 laser treatments, there was a 5,3 p. cent failure rate with the cervical condylomata, and 33,3 p. cent with the vulvovaginal condylomata. In the group treated by CO2 laser and Isoprinosine, there were 6,9 p. cent failures in patients with cervical condylomata and 5,7 p. cent failures in those with vulvovaginal condylomata following the initial treatment. After 3 treatments there were no failures. The combined use of CO2 laser and Isoprinosine reduces significantly the number of recurring condyloma acuminata, and appears to us to be an effective form of treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6085416

Source DB:  PubMed          Journal:  Rev Fr Gynecol Obstet        ISSN: 0035-290X


  4 in total

1.  Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study.

Authors:  J Davidson-Parker; W Dinsmore; M H Khan; D A Hicks; C A Morris; D F Morris
Journal:  Genitourin Med       Date:  1988-12

Review 2.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 3.  A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients.

Authors:  Stefan Miladinov Kovachev
Journal:  Infect Drug Resist       Date:  2021-06-02       Impact factor: 4.003

Review 4.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.